Zanoprima Files Patent Infringement Actions Against Hangsen to Enforce Its Groundbreaking Enzymatic Process for Synthesizing (S)-Nicotine
PR95226
Zanoprima Lifesciences Files Patent Infringement Actions Against Hangsen International to Enforce Its Groundbreaking Enzymatic Process for Synthesizing (S)-Nicotine
WACO, Texas, March 30, 2022 /PRNewswire=KYODO JBN/ --
On March 12, 2022, Zanoprima Lifesciences Ltd. ("Zanoprima") filed a Complaint
for Patent Infringement (
) against Hangsen International Group Ltd. ("Hangsen") in the U.S. District
Court, Civil No. 22-cv-00268 ("Complaint"). In its Complaint, Zanoprima alleges
that Hangsen has violated its patent entitled "Process for Making
(S)-Nicotine," (U.S. Patent No. 10,913,962 (
)) ("Zanoprima's Patent") through Hangsen's manufacture and importation into
the U.S. market products containing synthetic nicotine that are manufactured
using Zanoprima's patented process.
Zanoprima is the first company to manufacture and make commercially available
an enzymatically synthesized form of pure (S)-nicotine – SyNic (TM) – that is
chemically identical to that derived from a tobacco plant but devoid of harmful
tobacco-specific nitrosamines, carcinogens, alkaloids, and other impurities
that accompany tobacco-derived nicotine.
Ashok Narasimhan, CEO of Zanoprima, stated, "Over many years, Zanoprima has
invested substantial time, resources, intellectual capital, and scientific
expertise into developing Zanoprima's groundbreaking enzymatic patented process
for synthesizing an (S)-nicotine that is devoid of tobacco-specific
nitrosamines and other impurities. Zanoprima's legal action reflects our
company's dedication to vigorously protecting our intellectual property in the
U.S. and around the world."
Zanoprima's complaint alleges that, after publication of Zanoprima's Patent,
Hangsen filed a Chinese Patent Application describing a process that copied the
process invented by Zanoprima, but Hangsen's patent application was rejected by
the Chinese Patent Office in June 2021 citing Zanoprima's patent as prior art.
The Complaint also alleges Hangsen imports into the U.S. and sells products
containing "alleged high-purity synthetic (S)-nicotine and nicotine products
that are marketed and sold under various names including MOTiVO Synthetic
S-Nicotine," and that such imported products "are manufactured by a process
that practices every step of claim 1" of the Zanoprima Patent.
In addition to seeking damages for infringement, Zanoprima seeks preliminary
and permanent injunctive relief to prevent Hangsen from continuing its
infringing actions.
"Zanoprima's process for manufacturing SyNic (TM) represents a technological
innovation that provides a fully traceable (S)-nicotine, with high levels of
enantiomeric and chemical purity, which is commercially available at prices
that rival that of tobacco-derived nicotine. Further, SyNic (TM) represents the
greatest opportunity to facilitate the movement towards a tobacco free world,"
Mr. Narasimhan said.
READ THE FULL RELEASE HERE ( https://www.zanoprima.com/updates ).
SOURCE: Zanoprima Lifesciences Ltd.
CONTACT: Daniel Prati, Esq., Norton Rose Fulbright,
daniel.prati@nortonrosefulbright.com; Marc Collier, Esq., Norton Rose
Fulbright, marc.collier@nortonrosefulbright.com
本プレスリリースは発表元が入力した原稿をそのまま掲載しております。また、プレスリリースへのお問い合わせは発表元に直接お願いいたします。
このプレスリリースには、報道機関向けの情報があります。
プレス会員登録を行うと、広報担当者の連絡先や、イベント・記者会見の情報など、報道機関だけに公開する情報が閲覧できるようになります。